



Final Appraisal Recommendation

Advice number: 0124 – April 2024

Trifarotene (Aklief®▼) 50 microgram/g cream

Limited submission by Galderma (UK) Ltd

Recommendation of the All Wales Medicines Strategy Group

Trifarotene (Aklief®▼) is recommended as an option for use within NHS Wales for the cutaneous treatment of Acne Vulgaris of the face and/or the trunk in patients from 12 years of age and older, when many comedones, papules and pustules are present.

Additional note(s):

- Please refer to the Summary of Product Characteristics for the full licensed indication.
- The Medicines and Healthcare products Regulatory Agency (MHRA) advises use of topical retinoids is contraindicated during pregnancy as a precaution; the MHRA advises females of childbearing potential should use effective contraception.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3153), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review after three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation –
0124:
Trifarotene (Aklief®▼) 50 microgram/g cream April 2024